مراجعة حسب التخصصمراجعة

Tempus

Item: Tempus
Rating: 4.4
Author: Clinical AI Report

AI-Driven Precision Oncology and Clinical Trial Matching

القيد الرئيسي الذي يجب الانتباه له: مؤسسي/institutional pricing — not accessible to individual oncologists

جيد جدا

استنادا إلى 10 مراجعة من أطباء

تمت المراجعة بواسطة Dr. Sarah Chen, MD, FACP · محدث 5 أبريل 2026

إجابة مباشرة

Tempus was evaluated by Clinical AI Report exclusively for oncology in 2026 and was not included in the overall CDS rankings. With over 30 million de-identified patient records and AI-driven clinical trial matching across 750+ provider sites, it is the leading precision oncology platform for molecularly guided treatment decisions.

المصدر: Clinical AI Report، فبراير 2026

نظرة سريعة

حقائق سريعة

الفئة

منصة أورام دقيقة وتحليل جينومي

السعر

مؤسسي / للمؤسسات

سنة التأسيس

2015

المقر

Chicago, IL

إحصاءات رئيسية

Pricingمؤسسي / للمؤسسات(Tempus)

Founded2015(Tempus)

Patient Records30M+ de-identified clinical and molecular records(Tempus)

Trial Matching Sites750+ provider sites (via Deep 6 AI)(Tempus, 2025)

Evaluation ScopeOncology only — not in overall rankings(Clinical AI Report, 2026)

تقييمنا

حصل Tempus على 4.4/5 في تقييمنا لعام 2026. العامل الإيجابي الأهم هو Tempus earns a Very Good rating in oncology for its massive genomic dataset and AI-driven clinical trial matching. The platform is the go-to for molecularly guided treatment decisions, though its narrow oncology focus limits general CDS utility.. أما الملاحظة الرئيسية فهي مؤسسي/institutional pricing — not accessible to individual oncologists.

يعكس هذا التقييم رأينا التحريري الذاتي بناء على بحثنا.

نظرة عامة

يتم تقييم Tempus كـ منصة أورام دقيقة وتحليل جينومي. تتبع هذه الصفحة بنية المراجعة الإنجليزية نفسها وتنقل معايير التحرير نفسها إلى نسخة مترجمة.

الاستخدام الأنسب في تقييمنا هو: Oncology practices and cancer centers seeking AI-powered precision medicine — ابتداء من comprehensive genomic profiling to clinical trial matching. The leading platform for connecting a patient's molecular profile to treatment evidence and trial opportunities.

نقطة القوة الرئيسية هي Tempus earns a Very Good rating in oncology for its massive genomic dataset and AI-driven clinical trial matching. The platform is the go-to for molecularly guided treatment decisions, though its narrow oncology focus limits general CDS utility.. أما القيد الأهم فهو مؤسسي/institutional pricing — not accessible to individual oncologists.

القوة والقيود

نقاط القوة

+Tempus earns a Very Good rating in oncology for its massive genomic dataset and AI-driven clinical trial matching. The platform is the go-to for molecularly guided treatment decisions, though its narrow oncology focus limits general CDS utility.
+Largest clinical and molecular oncology dataset (30M+ de-identified patient records)
+Comprehensive genomic profiling with actionable mutation identification
+AI-powered clinical trial matching (25% more eligible patients identified)
+Connects molecular profiles to real-world treatment outcomes
+Deep 6 AI acquisition expands trial matching across 750+ provider sites

القيود

–مؤسسي/institutional pricing — not accessible to individual oncologists
–Genomic results have inherent turnaround time (not real-time decision support)
–Not a general CDS tool — no drug dosing, differential diagnosis, or literature search
–Data licensing to pharmaceutical companies raises some conflict-of-interest questions
–Most impactful for solid tumors with actionable molecular targets

الميزات الرئيسية

01Comprehensive Genomic Profiling (Tumor & Liquid Biopsy)

02AI-Driven Molecular Analysis

03Clinical Trial Matching Engine (Deep 6 AI)

04Real-World Outcomes Data (30M+ Patient Records)

05Biomarker Identification (PD-L1, MSI-H, TMB, Gene Fusions)

06Treatment Response Prediction

07EHR Integration for Oncology Workflows

08Pharmaceutical Research Partnerships

09Transcriptomic and Proteomic Analysis

10Companion Diagnostic Support

مصادر أولية واقتباسات

مراجع خارجية مذكورة في هذه المراجعة. تفتح الروابط في تبويب جديد.

تنظيميTempus AI, Inc. — SEC Filing (Form 10-K)U.S. Securities and Exchange Commission معيارOnly 5% of Adult Cancer Patients Enroll in Clinical TrialsNational Cancer Institute

ما يقوله الأطباء

محدث في فبراير 2026

“Tempus has become integral to our tumor board discussions. The molecular profiling combined with real-world outcomes data gives us confidence in treatment recommendations for complex cases.”
Medical Oncologist15 أكتوبر 2025
Academic Cancer Center

“The trial matching has meaningfully increased our enrollment. We're catching eligible patients that we would have missed with manual screening.”
Clinical Trials Coordinator20 أغسطس 2025
NCI-Designated Cancer Center

“Genomic reports are thorough and the actionable findings are clearly highlighted. Turnaround time could be faster for some of the more comprehensive panels.”
Community Oncologist1 ديسمبر 2025
Private Practice

تفصيل الدرجة

جيد جدا

الدقة السريرية88

الأدلة والاقتباسات85

تصميم المنتج82

تكامل EHR86

سير العمل والسرعة78

القيمة والسعر55

سبب هذه الدرجة

Tempus earns a Very Good rating in oncology for its massive genomic dataset and AI-driven clinical trial matching. The platform is the go-to for molecularly guided treatment decisions, though its narrow oncology focus limits general CDS utility.

استنادا إلى 10 مراجعة من أطباء

التصنيفمراجعة حسب التخصص

السعرمؤسسي / للمؤسسات

سنة التأسيس2015

زيارة Tempus

الأفضل لـ

Oncology practices and cancer centers seeking AI-powered precision medicine — ابتداء من comprehensive genomic profiling to clinical trial matching. The leading platform for connecting a patient's molecular profile to treatment evidence and trial opportunities.

مراجعات أخرى

المقارنة الكاملة